Functional analysis of CD44 variants and xCT in canine tumours

Atsushi Tanabe1, Kento Kimura1, Hana Tazawa1

  • 1Laboratory of Biology, School of Veterinary Medicine, Azabu University, Kanagawa, Japan.

Insights

CD44v8-10 and xCT transporter promote glutathione synthesis, enhancing cancer cell resistance to oxidative stress and radiation. These findings suggest CD44v8-10 and xCT are key factors in canine and human tumor therapy resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The CD44 glycoprotein exhibits diverse splicing variants influencing cellular functions.
  • The CD44v8-10 isoform interacts with xCT, inhibiting reactive oxygen species by boosting glutathione synthesis in human tumors.

Purpose of the Study:

  • Investigate CD44 variants and xCT expression and function in canine tumors.
  • Determine the role of CD44v8-10 and xCT in canine tumor therapy resistance.

Main Methods:

  • Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) for mRNA expression analysis.
  • Treatment of canine tumor cells with the xCT inhibitor sulfasalazine.
  • Assessment of cell sensitivity to oxidative stress.

Main Results:

  • CD44v8-10 mRNA was detected in canine tumor tissues.
  • Overexpression of CD44v8-10 correlated with enhanced glutathione synthesis and potential radiation resistance in canine breast tumors.
  • Canine xCT mRNA was upregulated in tumor tissues compared to normal tissues.
  • Sulfasalazine treatment increased canine tumor cell sensitivity to oxidative stress.

Conclusions:

  • CD44v8-10 and xCT are implicated in therapy resistance in both canine and human tumors.
  • Targeting CD44v8-10 and xCT may offer therapeutic strategies for canine cancers.

Related Concept Videos